Alector, Inc. (NASDAQ:ALEC) Receives $14.50 Average Price Target from Analysts

Shares of Alector, Inc. (NASDAQ:ALEC) have earned a consensus rating of “Moderate Buy” from the seven research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $14.50.

Separately, HC Wainwright reiterated a “buy” rating and issued a $41.00 target price on shares of Alector in a research report on Wednesday, February 28th.

Insider Activity at Alector

In other Alector news, CEO Arnon Rosenthal sold 18,837 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $130,352.04. Following the transaction, the chief executive officer now owns 2,000,380 shares of the company’s stock, valued at $13,842,629.60. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Alector news, insider Gary Romano sold 6,001 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $6.92, for a total value of $41,526.92. Following the transaction, the insider now owns 196,313 shares of the company’s stock, valued at $1,358,485.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Arnon Rosenthal sold 18,837 shares of the business’s stock in a transaction on Monday, March 4th. The shares were sold at an average price of $6.92, for a total value of $130,352.04. Following the completion of the sale, the chief executive officer now owns 2,000,380 shares in the company, valued at $13,842,629.60. The disclosure for this sale can be found here. Insiders have sold a total of 30,554 shares of company stock valued at $211,434 over the last 90 days. Insiders own 14.00% of the company’s stock.

Institutional Trading of Alector

Several hedge funds have recently made changes to their positions in ALEC. Raymond James & Associates bought a new stake in shares of Alector during the 1st quarter valued at $1,106,000. Bank of New York Mellon Corp raised its stake in shares of Alector by 1.0% during the 1st quarter. Bank of New York Mellon Corp now owns 206,696 shares of the company’s stock valued at $2,945,000 after purchasing an additional 1,983 shares during the period. American Century Companies Inc. raised its stake in shares of Alector by 84.7% during the 1st quarter. American Century Companies Inc. now owns 140,887 shares of the company’s stock valued at $2,008,000 after purchasing an additional 64,589 shares during the period. AlphaCrest Capital Management LLC bought a new stake in shares of Alector during the 1st quarter valued at $404,000. Finally, MetLife Investment Management LLC raised its stake in shares of Alector by 54.9% during the 1st quarter. MetLife Investment Management LLC now owns 31,825 shares of the company’s stock valued at $454,000 after purchasing an additional 11,276 shares during the period. 85.83% of the stock is currently owned by institutional investors.

Alector Stock Performance

NASDAQ:ALEC opened at $5.07 on Friday. The stock has a fifty day moving average price of $6.23 and a 200-day moving average price of $6.21. The company has a market cap of $485.45 million, a price-to-earnings ratio of -3.27 and a beta of 0.79. Alector has a fifty-two week low of $3.66 and a fifty-two week high of $9.06.

Alector (NASDAQ:ALEC) last announced its quarterly earnings data on Tuesday, February 27th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.80) by $0.31. Alector had a negative return on equity of 77.15% and a negative net margin of 134.34%. The business had revenue of $15.19 million during the quarter, compared to the consensus estimate of $8.35 million. Research analysts predict that Alector will post -1.85 EPS for the current fiscal year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.